Top Key Companies for Epidemic Cerebrospinal Meningitis Vaccines Market: Pfizer, Sanofi Pasteur, GSK, Hulan Bio, Lanzhou Institute of Biological Products, Tianyuan biology, Walvax, Zhifei.
Global Epidemic Cerebrospinal Meningitis Vaccines Market Size was estimated at USD 667.19 million in 2022 and is projected to reach USD 906.95 million by 2028, exhibiting a CAGR of 5.25% during the forecast period.
Global Epidemic Cerebrospinal Meningitis Vaccines Market Overview And Scope:
The Global Epidemic Cerebrospinal Meningitis Vaccines Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Epidemic Cerebrospinal Meningitis Vaccines utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Epidemic Cerebrospinal Meningitis Vaccines Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Epidemic Cerebrospinal Meningitis Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Epidemic Cerebrospinal Meningitis Vaccines market.
Global Epidemic Cerebrospinal Meningitis Vaccines Market Segmentation
By Type, Epidemic Cerebrospinal Meningitis Vaccines market has been segmented into:
Group A and Group C Meningococcal Polysaccharide Vaccine
Group A and Group C Meningococcal Conjugate Vaccine
Group ACYW135 Meningococcal Polysaccharide Vaccine
Group ACYW135 Meningococcal Conjugate Vaccine
Group A Meningococcal Polysaccharide Vaccine
Mmeningococcal Group B Vaccine
By Application, Epidemic Cerebrospinal Meningitis Vaccines market has been segmented into:
Under 1 Year Old
1 Year Old and Above
Regional Analysis of Epidemic Cerebrospinal Meningitis Vaccines Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Epidemic Cerebrospinal Meningitis Vaccines Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Epidemic Cerebrospinal Meningitis Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Epidemic Cerebrospinal Meningitis Vaccines market.
Top Key Companies Covered in Epidemic Cerebrospinal Meningitis Vaccines market are:
Pfizer
Sanofi Pasteur
GSK
Hulan Bio
Lanzhou Institute of Biological Products
Tianyuan biology
Walvax
Zhifei
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Epidemic Cerebrospinal Meningitis Vaccines Market by Type
5.1 Epidemic Cerebrospinal Meningitis Vaccines Market Overview Snapshot and Growth Engine
5.2 Epidemic Cerebrospinal Meningitis Vaccines Market Overview
5.3 Group A and Group C Meningococcal Polysaccharide Vaccine
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Group A and Group C Meningococcal Polysaccharide Vaccine: Geographic Segmentation
5.4 Group A and Group C Meningococcal Conjugate Vaccine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Group A and Group C Meningococcal Conjugate Vaccine: Geographic Segmentation
5.5 Group ACYW135 Meningococcal Polysaccharide Vaccine
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Group ACYW135 Meningococcal Polysaccharide Vaccine: Geographic Segmentation
5.6 Group ACYW135 Meningococcal Conjugate Vaccine
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Group ACYW135 Meningococcal Conjugate Vaccine: Geographic Segmentation
5.7 Group A Meningococcal Polysaccharide Vaccine
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2026-2035F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Group A Meningococcal Polysaccharide Vaccine: Geographic Segmentation
5.8 Mmeningococcal Group B Vaccine
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2026-2035F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Mmeningococcal Group B Vaccine: Geographic Segmentation
Chapter 6: Epidemic Cerebrospinal Meningitis Vaccines Market by Application
6.1 Epidemic Cerebrospinal Meningitis Vaccines Market Overview Snapshot and Growth Engine
6.2 Epidemic Cerebrospinal Meningitis Vaccines Market Overview
6.3 Under 1 Year Old
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Under 1 Year Old: Geographic Segmentation
6.4 1 Year Old and Above
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 1 Year Old and Above: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Epidemic Cerebrospinal Meningitis Vaccines Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Epidemic Cerebrospinal Meningitis Vaccines Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Epidemic Cerebrospinal Meningitis Vaccines Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 PFIZER
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 SANOFI PASTEUR
7.4 GSK
7.5 HULAN BIO
7.6 LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS
7.7 TIANYUAN BIOLOGY
7.8 WALVAX
7.9 ZHIFEI
Chapter 8: Global Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Group A and Group C Meningococcal Polysaccharide Vaccine
8.2.2 Group A and Group C Meningococcal Conjugate Vaccine
8.2.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
8.2.4 Group ACYW135 Meningococcal Conjugate Vaccine
8.2.5 Group A Meningococcal Polysaccharide Vaccine
8.2.6 Mmeningococcal Group B Vaccine
8.3 Historic and Forecasted Market Size By Application
8.3.1 Under 1 Year Old
8.3.2 1 Year Old and Above
Chapter 9: North America Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine
9.4.2 Group A and Group C Meningococcal Conjugate Vaccine
9.4.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
9.4.4 Group ACYW135 Meningococcal Conjugate Vaccine
9.4.5 Group A Meningococcal Polysaccharide Vaccine
9.4.6 Mmeningococcal Group B Vaccine
9.5 Historic and Forecasted Market Size By Application
9.5.1 Under 1 Year Old
9.5.2 1 Year Old and Above
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine
10.4.2 Group A and Group C Meningococcal Conjugate Vaccine
10.4.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
10.4.4 Group ACYW135 Meningococcal Conjugate Vaccine
10.4.5 Group A Meningococcal Polysaccharide Vaccine
10.4.6 Mmeningococcal Group B Vaccine
10.5 Historic and Forecasted Market Size By Application
10.5.1 Under 1 Year Old
10.5.2 1 Year Old and Above
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine
11.4.2 Group A and Group C Meningococcal Conjugate Vaccine
11.4.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
11.4.4 Group ACYW135 Meningococcal Conjugate Vaccine
11.4.5 Group A Meningococcal Polysaccharide Vaccine
11.4.6 Mmeningococcal Group B Vaccine
11.5 Historic and Forecasted Market Size By Application
11.5.1 Under 1 Year Old
11.5.2 1 Year Old and Above
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine
12.4.2 Group A and Group C Meningococcal Conjugate Vaccine
12.4.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
12.4.4 Group ACYW135 Meningococcal Conjugate Vaccine
12.4.5 Group A Meningococcal Polysaccharide Vaccine
12.4.6 Mmeningococcal Group B Vaccine
12.5 Historic and Forecasted Market Size By Application
12.5.1 Under 1 Year Old
12.5.2 1 Year Old and Above
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine
13.4.2 Group A and Group C Meningococcal Conjugate Vaccine
13.4.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
13.4.4 Group ACYW135 Meningococcal Conjugate Vaccine
13.4.5 Group A Meningococcal Polysaccharide Vaccine
13.4.6 Mmeningococcal Group B Vaccine
13.5 Historic and Forecasted Market Size By Application
13.5.1 Under 1 Year Old
13.5.2 1 Year Old and Above
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Epidemic Cerebrospinal Meningitis Vaccines Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine
14.4.2 Group A and Group C Meningococcal Conjugate Vaccine
14.4.3 Group ACYW135 Meningococcal Polysaccharide Vaccine
14.4.4 Group ACYW135 Meningococcal Conjugate Vaccine
14.4.5 Group A Meningococcal Polysaccharide Vaccine
14.4.6 Mmeningococcal Group B Vaccine
14.5 Historic and Forecasted Market Size By Application
14.5.1 Under 1 Year Old
14.5.2 1 Year Old and Above
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Epidemic Cerebrospinal Meningitis Vaccines Scope:
|
Report Data
|
Epidemic Cerebrospinal Meningitis Vaccines Market
|
|
Epidemic Cerebrospinal Meningitis Vaccines Market Size in 2025
|
USD XX million
|
|
Epidemic Cerebrospinal Meningitis Vaccines CAGR 2025 - 2032
|
XX%
|
|
Epidemic Cerebrospinal Meningitis Vaccines Base Year
|
2024
|
|
Epidemic Cerebrospinal Meningitis Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Pfizer, Sanofi Pasteur, GSK, Hulan Bio, Lanzhou Institute of Biological Products, Tianyuan biology, Walvax, Zhifei.
|
|
Key Segments
|
By Type
Group A and Group C Meningococcal Polysaccharide Vaccine
Group A and Group C Meningococcal Conjugate Vaccine
Group ACYW135 Meningococcal Polysaccharide Vaccine
Group ACYW135 Meningococcal Conjugate Vaccine
Group A Meningococcal Polysaccharide Vaccine
Mmeningococcal Group B Vaccine
By Applications
Under 1 Year Old
1 Year Old and Above
|
